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Abstract:
Background:
Worldwide antibiotic abuse represents a huge burden, which can have a deep impact on pet and human health through nutrition and
medicalization representing another way of antibiotic resistance transmission.
Objective:
We  aimed  our  research  to  determine  a  possible  complex  formation  between  biological  bone  substrates,  such  as  proteins,  and
Oxytetracycline (OTC), an approved antibiotic for use in zootechny, which might determine a toxic effect on K562 cells.
Method:
Cell viability and HPLC-ESI/QqToF assays were used to assess potential toxicity of bone extract derived from OTC-treated chickens
according to standard withdrawal times and from untreated chickens at 24, 48 and 72h of incubation.
Results:
Cell culture medium with ground bone from chickens reared in the presence of OTC (OTC-CCM) resulted significantly cytotoxic at
every incubation time regardless of the bone concentration while cell culture medium with ground bone from chickens reared without
OTC (BIO-CCM)  resulted  significantly  cytotoxic  only  after  72h  of  incubation.  HPLC-ESI/QqToF  assay  ruled  out  the  possible
presence of OTC main derivatives possibly released by bone within culture medium until 1 μg/mL.
Conclusion:
The  presence  of  a  protein  complex  with  OTC  is  able  to  exert  a  cytotoxic  effect  once  released  in  the  medium  after  24-48h  of
incubation.
Keywords: Antibiotic abuse, Oxytetracycline, Protein complex, Cytotoxic effect, Pro-inflammatory effect, K562 cells.
1. INTRODUCTION
   Some studies  reveal  that  the  widespread antibiotic  use in  agriculture  and aquaculture  might  contribute to  the
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development  of  resistance  to  antibiotics  commonly  used  in  human  medicine  [1].  This  issue  becomes  important
particularly in zootechny due to its accumulation in animal feed and food with potential chronic consequences deriving
from its ingestion to the species fed with these foods [2].
Nowadays, antimicrobials use represents a serious concern particularly in two correlated fields i.e.  medical and
agricultural [2 - 5]. In poultry, for instance, antibiotics are used to promote growth and to treat, control, and prevent
overcrowding diseases [2, 6, 7]. A routinely exposure to antibiotics induce a selection for resistant bacteria that can
persist on meat and in animal waste with a vertical transmission through maternal generations of breeding stocks [7].
Such bacteria can get in contact with humans in food-animal production facilities, in meat processing plants but also
consuming contaminated meat  [6,  8 -  10].  Despite there is  not  a  common consensus on the use potential  antibiotic
resistance elicited by antibiotic used in animal food many countries have made substantial efforts to reduce the overall
use  of  antibiotics  in  food-producing  animals,  in  the  attempt  to  decrease  the  antibiotic  resistance  in  animals,  the
environment, and in human beings.
Moreover, Mueller et al.  hypothesized that food allergens e.g.  beef, fish and chicken could drag antibiotics and
hormones thus representing the cause for the onset of dermatological symptoms in cats [11]. Among pharmacologically
active substances, tetracyclines (in particular oxytetracycline, OTC) and their metabolites present in meats and meat-
based foods for humans and pets were considered and studied [9, 10, 12].
We  firstly  hypothesized  and  observed  the  role  of  OTC  as  an  underlying  cause  of  some  chronic  inflammatory
pathologies in vivo and in vitro as described by Di Cerbo et al. [8, 9, 13 - 17]. Due to its low cost and high efficacy [18],
OTC is widely employed in the intensive farming of poultry [2], livestock [19] and aquaculture [20]. However, OTC
has a high affinity for calcium, mainly present within bones, and a very low and long clearance in treated animals [21].
Further,  pet  food  production,  which  mainly  relies  on  poultry  by-products  [22],  also  avails  itself  of  an  important
percentage of bone meal (20-30%) [8] with a consequent dragging of OTC residues that are frequently found within
commercially available diets [10].
Despite the setting of maximum residue limits in foods by Food and Drug Administration [23] and World Health
Organization  [24]  OTC  residues  may  still  persist  since  bone  is  not  considered  as  an  edible  tissue,  thus  making
commercial pet food potentially harmful [25].
In  this  paper,  based  on  our  previous  results  [6,  21],  we  aimed  our  research  to  determine  possible  interactions
between biological substrates, such as proteins, and OTC, which might lead to an increased or decreased toxic effect on
K562 cells mediated by the antibiotic. For this purpose we evaluated the potential toxicity of bone extract derived from
OTC-treated chickens according to standard withdrawal times and from untreated chickens.
2. MATERIALS AND METHODS
2.1. Cell Culture
K562 myelogenous  leukemia  cell  line,  were  purchased  from American  Type  Culture  Collection  (ATCC)  (LGC
Standards srl, Milan, Italy). K562 cells were grown in RPMI supplemented with 10% Fetal Bovine Serum (FBS) 100
g/mL streptomycin, 100 U/mL penicillin, 2 mM glutamine (Euroclone Spa, Milan, Italy). The cells were cultured in a
humidified incubator at 37 °C with 95% and 5% CO2.
2.2. Conditioned Culture Medium Preparation
Conditioned Culture Medium (CCM) was obtained by incubating 10 mL of a RPMI 1640 cell culture medium with
124, 90, 6, 2.48 mg and 124 μg of sterilized ground bone from chickens reared in the presence (OTC-CCM) or absence
(BIO-CCM) of treatments with OTC and constantly shaken for 24-48-72 h at 37° C. After incubation, both CCMs were
filtered  through  0.45  and  0.20  μm syringe  filters  (Sartorius  Stedim Biotech,  Goettingen,  Germany)  to  remove  any
residual ground bone particles and microbial [21].
2.3. Determination of Cell Viability
Cell viability was assessed after 24-48-72 h of continuous exposure with the aforementioned concentrations. A Cell
Counting Kit-8  (CCK-8)  assay (Dojindo Laboratories,  Kumamoto,  Japan)  was used to  measure  the  cytotoxicity  on
K562 cells. Briefly, the K562 cells were plated on 96-well plates (Euroclone, Milan, Italy) at concentration of 5000 or
10000 cells/cm2. After exposure to desired concentrations of the different compounds, 10µl of CCK-solution was added
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to each well and incubated for a period of 2 h at 37°C. Finally, absorption was measured at 450 nm using a multiplate
reader Multiscan FC (Thermo Scientific, USA). Dimethyl Sulfoxide (DMSO) 3% was used as toxic reference drug. Cell
viability  was  expressed  as  a  percentage  of  that  of  the  untreated  cells  (Control).  For  each  concentration  of  tested
compounds, mean values of the mean absorbance rates from four wells were calculated.
2.4. HPLC-ESI/MS Analysis
CCM samples were analyzed using a HPLC-ESI/MS, analyses were performed on a 1200 Series HPLC coupled to
either  a  6520A  Quadrupole/Time-of-Flight  high  mass  spectrometer  (QqToF)  or  a  6410B  Triple  Quadrupole  mass
spectrometer (QqQ), (both from Agilent Technologies, California, USA) via an electrospray ion source (ESI). On the
HPLC-ESI/QqToF system, the chromatographic separation was carried out with 4 mL injection volume on an Agilent
Zorbax SB-C18 30 x 2.1 mm ID 3.5 mm ps column. Elution was performed at T=25°C, with a flow rate of 0.3 mL/min.
were used as a mobile phase. A linear gradient elution starting at 0.5 min going from 2% (B) up to 40% (B) in 11
minutes then up to 95% (B) in 6 minutes was performed using water with 0.5% formic acid (A) and Acetonitrile (B) as
mobile phase components. The mass spectrometer was operated in positive-ion mode (ESI+) using “Auto MS/MS”
acquisition with MS and MS/MS scan ranges being 50<m/z<1000 Th and selection of the top 3 most abundant mono-
charged ions from each MS scan for their subsequent MS/MS spectra acquisition (active exclusion was enabled after 1
spectrum and released after 0.15 min). Targeted MS/MS analyses on the HPLC-ESI/QqQ included chromatographic
separation on an Agilent Zorbax SB-C18 30 x 2.1 mm ID 3.5 mm ps column at 0.3 ml/min with the following gradient
(mobile phases: A: water + 0.1 FA%, B: acetonitrile + 0.1 FA%): 0’ 98:2 A:B, kept for 0.5’ then B% was raised to 40%
in 11’, then B% was raised to 95% in 3’, hold for 6’ then columns was reconditioned at the starting conditions, for a
total runtime of 32 minutes.
ESI source was operated in positive mode at 3.5 KV, the Gas Heater was set to 300°C, the gas flow was 8 l/min and
the nebulizer pressure was set to 25 psi.
Three transitions for OTC were chosen for Selected Reaction Monitoring, as shown in the Table (1).
Table 1. Selected Reaction Monitoring for the three transitions of OTC.
Precursor (m/z) Product (m/z) Fragmentor (V) CE (V) Dwell Time (ms)
461.5 426.4 106 17 400
461.5 286.1 106 25 100
461.5 201.2 106 29 100
A matrix-matched calibration curve was prepared, ranging from 1 ppb to 1 ppm OTC concentration on a diluted and
filtered  CCM; samples  were  filtered,  diluted  at  the  same dilution  factor  of  the  calibration  curve  and  analyzed.  For
standard-addition method, the sample was spiked with OTC ranging from 1 ppb to 1 ppm.
2.5. Statistical Analysis
All data are presented as the mean ± SD of at least three different experiments done in quadruplicate. One-way
ANOVA analysis of variance with Dunnett’s post-test, were performed to compare differences between the groups, as
indicated in the figures (Graph-Pad 6 Software Inc., San Diego, CA, USA). P values < 0.05 were considered significant.
3. RESULT
Here  we found that  OTC-CCM resulted  significantly  cytotoxic  at  every  incubation  time regardless  of  the  bone
concentration while BIO-CCM resulted significantly cytotoxic only after 72h of incubation Fig. (1).
Qualitative analysis was performed using the HPLC-ESI/QqToF assay in order to test for the presence of OTC (at a
concentration  ≥  1mg/mL)  and  its  main  derivatives  N-Demethyloxytetracycline,  N-Didemethyloxytetracycline,  and
Apooxytetracycline. To this purpose, their presence was tested using their molecular ion signals eventually revealed on
their respective Extracted Ion Chromatogram (EIC) in the ESI(+) MS experiments. Due to the QqToF high resolution
and mass accuracy (< 5 ppm) each EIC was obtained using a  narrow extraction window (10 ppm) centered on the
molecular ion theorical m/z value. In order to account for the eventual suppression of OTC signals at the 1 mg/mL
concentration level, due to matrix effect in extracted samples or for its degradation/combination in the extracted sample
environment, extracted samples were as well spiked with OTC at 1 μg/mL and analyzed right away (t0) and after 24 and
48 hours (t 24, t 48). Neither OTC nor its derivatives were revealed in non-spiked OTC-CCM and BIO-CCM extracted
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samples Figs. (2, 3) while OTC molecular ion ([M+H]+ at m/z= 461.155) was clearly revealed in t 0, t 24 and t 48
spiked samples  with  roughly  the  same signal  intensity  (within  the  instrument  variability).  This  suggested  the  OTC
concentration  being  substantially  below  the  tested  1  μg/mL  level,  while  reasonably  excluding  strong
degradation/combination  reactions  of  OTC in  the  extracted  matrix  environment  at  least  within  the  tested  48  hours
period.
Fig.  (1).  Graphical  representation  of  the  effects  of  conditioned  medium with  bone  with  (OTC-CCM)  and  without  (BIO-CCM)
oxyteracycline on K562 cell line at different incubation times (24, 48 and 72h) and at different bone concentrations (124, 90, 6, 2.48
mg and 124 μg). *p < 0.05, ***p < 0.001 vs Control (Ctrl).
Targeted MS/MS analyses were performed on the HPLC-ESI/QqQ to quantitate OTC in bone samples. Preliminary
tests showed a heavy matrix effect, thus we optimized the dilution factor and injection volumes for best results, ending
up with a 20-fold dilution and 20 μl of diluted sample injected.
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Fig. (2). From top, ESI(+) MS EIC of m/z 461.155 ion shown in the retention window of OTC in OSSO BIO non-spiked, t0, t24 and
t48 samples.
Fig. (3). From the top, ESI(+) MS EIC of m/z 461.155 ion shown in the retention window of bone with OTC non-spiked at 0, 24 and
48h.
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Matrix-matched calibration curve showed a good fit (r2 ≥ 0.999); unfortunately, the sample signal was below the
quantification limit. In order to increase the sensitivity because of the low concentration of OTC in analyzed samples,
standard-addition method was applied. In this case, by extrapolating the intercept of the curve on the y-axis we were
able to determine OTC concentration. By correcting the value for the dilution factor, the final determined concentration
was 200 ng/ml. As a proof of concept, we ran the same standard addition analysis on the organic bone extract; the curve
in this case showed an intercept with the y-axis significantly closer to the origin, indicating that the concentration of
OTC (if any) was significantly lower in this extract compared to the bone extract Fig. (4).
Fig. (4). Triple Quadrupole mass spectrometer (QqQ-ESI) molecular iron determination of OTC-protein complex.
4. DISCUSSION
Previously published data showed a significant cytotoxic effect of OTC powder at 24, 48 and 72h at a concentration
of 150 μg/mL (according to the amount of OTC expected to be provided to chicken during a standard treatment and
disclosed on the antibiotic package) and at 48 and 72h at 75 and 35 μg/mL [8]. Moreover, the cytotoxic effect was
clearly visible at OTC concentrations far below those previously investigated [10].
We  recently  claimed  the  unavoidable  occurrence  of  oxytetracycline  as  a  contaminant  of  meat,  bone  meal  and
poultry  by-products,  which  are  widely  present  within  commercially  available  pet  diets  and  human  foods  (mainly
würstels and sausages) [8, 10]. In addition, we reported a discrepancy among OTC kibble concentration, OTC serum
concentration of dogs with dermatitis and otitis, diarrhea and general anxiety and in vitro OTC, 20% liquid or powder,
last cytotoxic concentration [10]. In fact, OTC kibble concentration was 19 μg/mL, serum oxytetracycline concentration
was 0.22 μg/mL while in vitro last cytotoxic concentration was 35 μg/mL for the OTC powder and 87.5 μg/mL for the
20% liquid OTC.
Despite our in vitro data are in agreement with those previously published [6, 10], it is worth noting that HPLC-
ESI/QqToF clearly evidenced the lack of OTC and its  main derivatives within conditioned medium until  1 μg/mL.
However the results obtained with Triple Quadrupole mass spectrometer (QqQ) showed the presence of an OTC-protein
complex
This latter result helped us to rule out the toxic role of OTC itself and allowed us to speculate the presence of a
protein  complex  inside  bone  with  OTC able  to  exert  a  cytotoxic  and  pro-inflammatory  effect  once  released  in  the
medium after 24-48h of incubation. Moreover, it is reasonable to hypothesize that most of symptoms observed in the
dogs of our previous paper might be due to an overall inflammatory condition elicited by the daily intake of kibbles
made of chicken-derived bone with OTC. Although more researches are needed in order to figure out the chemical
composition of  the complex and the molecular  mechanism involved in the cell  toxicity,  our results  revealed a new
possible explanation linked to the side effects of chicken-derived bone with OTC.
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CONCLUSION
Our research represents a further insight into the overall landscape of antimicrobials abuse pointing out the possible
consequences  on  pets  and  humans  well  being  with  particular  regard  to  the  actual  antibiotic  resistance  spread.
Unfortunately, WHO and FDA have set high OTC minimal residual limits within organs of farmed animals and do not
consider bone as a possible veihicle of contamination since considered as not edible [8, 26]. In this view our findings
rise new questions concerning the interactions between antibiotics, i.e. OTC, and organic substrates. Indeed our results
pointed out the formation of a complex which induce cell toxicity even more then antibiotic alone. The further question
to be answerd is wether this complex is able to induce antibiotic resitence too.
Since WHO ruled out an agenda on the study and the prevention of antimcorobial resistence (AMR) in the different
fields  where  the  antibiotic  were  used,  further  studies  with  more  detailed  evaluations  are  needed  to  support  our
preliminary observations, and to confirm a possible new scenario in the AMR.
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